Dova Pharma

Dova Pharmaceuticals a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need. With a nimble approach and a team of bright minds aglow with passion, we’re dedicated to bringing brilliant medicine to market.

Shares of thinly traded small-cap biotech Dova Pharmaceuticals Inc (NASDAQ: DOVA) were solidly higher Thursday, adding to the gains they notched early in the week .

What's Driving The Rally At Small-Cap Biotech Dova?

Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.

Dova Receives Approval for Doptelet in Europe, Stock Up

Investors need to pay close attention to Dova Pharmaceuticals (DOVA) stock based on the movements in the options market lately.

Implied Volatility Surging for Dova Pharmaceuticals (DOVA) Stock Options

Dova Pharmaceuticals' (DOVA) CEO David Zaccardelli on Q1 2019 Results - Earnings Call Transcript

Dova Pharmaceuticals (DOVA) delivered earnings and revenue surprises of 14.71% and 15.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Dova Pharmaceuticals (DOVA) Reports Q1 Loss, Tops Revenue Estimates

Dova Pharmaceuticals reported Q4 earnings that were almost in line with expectations. There was a beat in EPS but a slight miss in revenue.

News for Dova Pharma Stock (DOVA)